Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000493014 | SCV000582727 | pathogenic | not provided | 2023-10-04 | criteria provided, single submitter | clinical testing | Not observed in large population cohorts (gnomAD); Nonsense variant in the C-terminus predicted to result in protein truncation, as the last 46 amino acids are lost, and other loss-of-function variants have been reported downstream in the Human Gene Mutation Database (HGMD); This variant is associated with the following publications: (PMID: 22045651, 22460224, 29604340, 31440721) |
Center for Human Genetics, |
RCV000660298 | SCV000782335 | likely pathogenic | Pitt-Hopkins syndrome | 2016-11-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000660298 | SCV000819174 | pathogenic | Pitt-Hopkins syndrome | 2022-09-30 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. ClinVar contains an entry for this variant (Variation ID: 430016). This premature translational stop signal has been observed in individual(s) with Pitt–Hopkins Syndrome (PMID: 22045651). This variant is not present in population databases (gnomAD no frequency). This sequence change creates a premature translational stop signal (p.Arg626*) in the TCF4 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in TCF4 are known to be pathogenic (PMID: 18728071, 22045651). |
Institute of Medical Genetics and Applied Genomics, |
RCV000493014 | SCV001446521 | pathogenic | not provided | 2020-10-23 | criteria provided, single submitter | clinical testing | |
Foundation for Research in Genetics and Endocrinology, |
RCV000660298 | SCV002762860 | pathogenic | Pitt-Hopkins syndrome | 2020-12-23 | criteria provided, single submitter | research | A heterozygous nonsense variation in exon 19 of the TCF4 gene that results in a stop codon and premature truncation of the protein at codon 728 was detected. The observed variant c.2182C>T (p.Arg728Ter) has not been reported in the 1000 genomes and gnomAD databases. The in silico prediction of the variant is damaging by MutationTaster2. The reference codon is conserved across species. Segregation analysis showed this variant to be de novo. In summary, the variant meets our criteria to be classified as a pathogenic variant. |
Center For Human Genetics And Laboratory Diagnostics, |
RCV000660298 | SCV003035475 | pathogenic | Pitt-Hopkins syndrome | 2022-04-05 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003159600 | SCV003882800 | pathogenic | Inborn genetic diseases | 2023-02-14 | criteria provided, single submitter | clinical testing | The c.1876C>T (p.R626*) alteration, located in exon 18 (coding exon 17) of the TCF4 gene, consists of a C to T substitution at nucleotide position 1876. This changes the amino acid from an arginine (R) to a stop codon at amino acid position 626. This alteration is expected to result in loss of function by premature protein truncation or nonsense-mediated mRNA decay. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This variant has been identified in multiple individuals with clinical features of Pitt-Hopkins syndrome (Liu, 2018; Whalen, 2012). Based on the available evidence, this alteration is classified as pathogenic. |
Clinical Genetics Laboratory, |
RCV000493014 | SCV005198759 | pathogenic | not provided | 2022-05-27 | criteria provided, single submitter | clinical testing |